As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: February 8, 2012
Scientists in Nottingham have found abnormal levels of seven different proteins in spinal fluid could act as markers for detecting Alzheimer’s disease.
by Medical Xpress
The study, which was part-funded by Alzheimer’s Research UK, the UK’s leading dementia research charity, could lead to the development of a new test to detect the disease in its early stages.
Researchers at The University of Nottingham’s Human Genetics department and Nottingham Trent University’s John van Geest Cancer Research Centre studied samples of cerebrospinal fluid (CSF) to look for potential markers of Alzheimer’s. They compared CSF samples from 33 people with Alzheimer’s disease, 20 healthy older people and ten people with mild cognitive impairment (MCI) — a condition that causes problems with memory and thinking, but not to an extent that interferes with daily life.
Prof Kevin Morgan of The University of Nottingham, who co-authored the study, said: “Our results have given us a new lead for improving early diagnosis of Alzheimer’s disease. An early diagnosis would not only help people prepare for the future, but would also enable people to be involved in clinical trials at a much earlier stage, when new treatments are more likely to have a positive effect.
“It will also be important to investigate what causes these specific proteins to change as Alzheimer’s develops. If we can understand the biochemical changes that occur during Alzheimer’s, we stand a better chance of developing new treatments that can tackle the disease. Dementia can only be defeated through research, and I hope these findings could take us a step closer to that goal.”
The scientists first analysed each CSF sample to build a profile of the proteins it contained, and looked for patterns that could distinguish between people with Alzheimer’s and healthy people. They found people with the disease tended to have higher levels of four specific proteins, and lower levels of three other proteins, suggesting that together they could act as markers for the disease.
One protein in particular, called SPARCL1, was the strongest predictor for the disease. When the CSF samples were tested for changes in SPARCL1 alone, the researchers were able to detect whether a person had Alzheimer’s disease with 65 per cent accuracy. When they checked for abnormal levels of all seven proteins, accuracy improved to 95 per cent. The discovery of SPARCL1, amongst other proteins, resulted from the application of technologies developed at the John van Geest Cancer Research Centre.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.